Login

VALEANT PHARMACEUTICALS INTERNATIONAL 5 SEC Filings

Filed On Filing
10 Feb 2005 Form 5: Ullian Elaine, Director

Received 26 shares as a grant or award ($445) · Received 23 shares as a grant or award ($566)

10 Feb 2005 Form 5: Thurman Randy, Director

Received 38 shares as a grant or award ($907) · Received 36 shares as a grant or award ($919) · Received 89 shares as a grant or award ($1.52K) · 1 more

10 Feb 2005 Form 5: Melas Kyriazi Theo, Director

Received 27 shares as a grant or award ($644) · Received 25 shares as a grant or award ($638) · Received 64 shares as a grant or award ($1.1K) · 1 more

10 Feb 2005 Form 5: Kugelman Larry, Director

Received 27 shares as a grant or award ($644) · Received 25 shares as a grant or award ($638) · Received 64 shares as a grant or award ($1.1K) · 1 more

10 Feb 2005 Form 5: Koppes Richard, Director

Received 27 shares as a grant or award ($644) · Received 25 shares as a grant or award ($638) · Received 64 shares as a grant or award ($1.1K) · 1 more

10 Feb 2005 Form 5: Ingram Robert Alexander, Director

Received 27 shares as a grant or award ($644) · Received 25 shares as a grant or award ($638) · Received 64 shares as a grant or award ($1.1K) · 1 more

10 Feb 2005 Form 5: Burkhardt Edward A, Director

Received 26 shares as a grant or award ($445) · Received 22 shares as a grant or award ($541)

04 Feb 2004 Form 5: Lamon Kim David, Pres. & Chief Scientific Off.

Granted 405,055 Non-Qualified Stock Option (right to buy)

03 Feb 2004 Form 5: O Leary Robert, Director

Acquired 1,000 shares (Gift) · Gave 3,000 shares as a gift

04 Feb 2003 Form 5
04 Feb 2003 Form 5
04 Feb 2003 Form 5
04 Feb 2003 Form 5
04 Feb 2003 Form 5
04 Feb 2003 Form 5
04 Feb 2003 Form 5
04 Feb 2003 Form 5

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support